Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Endocrinology

Life After Treatment: Long-term Care and Transition

At a Glance

After treatment for pituitary gigantism, lifelong follow-up checks growth-related and other pituitary hormones, watches for tumor return and heart, blood sugar, sleep, and bone problems, and prepares patients for a safe transition to adult endocrinology.

Managing pituitary gigantism does not end once the initial treatment is over. Because children with this condition often have larger, more invasive tumors and a higher likelihood of genetic links, surveillance is a lifelong commitment [1][2]. While the initial phase of diagnosis may have passed, regular check-ups ensure that any recurrence is caught early and that the body remains healthy as patients grow into adulthood [3].

The Dual Path of Surveillance

Long-term monitoring follows two parallel tracks: biochemical (checking hormone levels) and anatomical (checking the brain for any changes).

  • Hormone Checks: Regular blood tests for age- and puberty-adjusted IGF-1 are the primary biochemical marker of control. Random GH tests fluctuate widely and are not reliable standalone markers, though dynamic GH tests may be used when indicated [4][5]. Monitoring usually begins 1–3 months after surgery and continues periodically for life, as recurrence can happen years later [6][7].
  • Imaging (MRI): A high-resolution MRI is typically performed months after surgery to establish a “new baseline” [8]. Future scans will be scheduled individually based on whether residual tumor was left behind and the treatments used [5][9].

Monitoring the Whole Pituitary

It is critical to monitor not just GH, but all the hormones that control the thyroid, the adrenal glands (ACTH/cortisol), and puberty (LH/FSH) [10][11]. The tumor itself, the surgery, or radiation therapy can damage healthy pituitary tissue [11].

  • Delayed Effects: If radiotherapy was received, deficiencies may not appear for months or years [12].
  • Adrenal Insufficiency: Untreated ACTH deficiency can be life-threatening. If prescribed steroid replacement, patients must wear medical alert identification and follow sick-day rules during illnesses.
  • Growth Hormone Deficiency: Paradoxically, a patient treated for excess growth hormone may eventually become Growth Hormone deficient [13]. If proven deficient and the tumor is stable, the care team may carefully weigh the risks and benefits of GH replacement therapy.

Monitoring Your Total Health

The effects of excess growth hormone can impact many systems in the body. Based on symptoms and risks, care may include screening for these comorbidities:

  • Heart Health: Excess GH can cause the heart muscle to thicken or lead to high blood pressure. Screenings, including EKGs or echocardiograms, may be recommended based on risk factors [14][15].
  • Metabolic Health: Growth hormone affects how the body handles sugar. Your team will monitor for glucose intolerance or diabetes, especially if medications like pasireotide were used [16][17].
  • Sleep and Breathing: Many patients develop obstructive sleep apnea. This can persist even after hormone levels are controlled, so sleep studies may be ordered if snoring or poor sleep is noted [18][19].
  • Bone and Joints: Rapid growth can lead to joint pain or hip issues like slipped capital femoral epiphysis. Bone health and fracture risk must be managed [20][21].

Life, School, and Transitioning to Adult Care

Survivorship involves more than medical tests; it includes managing school accommodations, mental health, body image, and discussing future fertility.

As a patient reaches their late teens, the transition from a pediatric hospital to an adult medical team must be carefully planned [22].

  • The Transition Plan: You and the pediatric team should create a written “summary of care.” This should include operative reports, pathology, genetic results, and a clear history of which medications worked and which did not [3][2].
  • Adult Specialists: You will need an adult endocrinologist who understands the unique challenges of pediatric-onset gigantism [23][3]. Continuing this care without interruption is the best way to ensure a long, healthy, and active life.

Common questions in this guide

How long does follow-up last after treatment for pituitary gigantism?
Follow-up is usually lifelong because the tumor can recur years after treatment and hormone problems may appear later. Visits commonly include age- and puberty-adjusted IGF-1 blood tests, other pituitary hormone tests, and imaging planned for your history.
How often will I need an MRI after pituitary gigantism surgery?
An MRI is usually done several months after surgery to create a new baseline. Later scans are scheduled based on whether any tumor remains and which treatments were used, so the interval differs from person to person.
What pituitary hormones need checking after treatment for pituitary gigantism?
Care teams monitor IGF-1 and may check thyroid hormones, cortisol-related adrenal function, and hormones that control puberty. Surgery or radiation can reduce normal pituitary function, and some deficiencies may not appear until months or years later.
What health problems can occur after pituitary gigantism?
Follow-up may include screening for heart muscle changes or high blood pressure, blood sugar problems, sleep apnea, and bone or joint problems. Snoring, poor sleep, joint pain, or low energy should be reported because they may prompt additional testing.
Can growth hormone be replaced after treatment for pituitary gigantism?
Possibly, but only when testing confirms growth hormone deficiency and the tumor is stable. The endocrinology team weighs potential benefits against the risk of stimulating tumor regrowth and monitors the patient closely.
How should a patient transition from pediatric to adult pituitary care?
The pediatric and adult teams should plan the transition together and prepare a written care summary. It should include operative and pathology reports, genetic results, treatment history, and current or past medicines so adult clinicians can continue care without gaps.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our plan for monitoring IGF-1 and other pituitary hormones, especially ACTH/cortisol and thyroid hormone, over the next five to ten years?
  2. 2.Based on the presence of any residual tumor on the post-op MRI, how often should we be doing follow-up scans?
  3. 3.If Growth Hormone replacement is considered later, how will you ensure that it doesn't cause the original tumor to regrow?
  4. 4.What specific heart, sleep, and bone screenings should we be doing, and how often based on the symptoms?
  5. 5.Can we schedule a 'transition visit' where we meet with the adult endocrinologist together to review the surgical and genetic history?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

    Rostomyan L, Daly AF, Petrossians P, et al.

    Endocrine-related cancer 2015; (22(5)):745-57 doi:10.1530/ERC-15-0320.

    PMID: 26187128
  2. 2

    Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

    Perry A, Graffeo CS, Marcellino C, et al.

    Journal of neurological surgery. Part B, Skull base 2018; (79(1)):91-114 doi:10.1055/s-0038-1625984.

    PMID: 29404245
  3. 3

    Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.

    Korbonits M, Blair JC, Boguslawska A, et al.

    Nature reviews. Endocrinology 2024; (20(5)):290-309 doi:10.1038/s41574-023-00949-7.

    PMID: 38336898
  4. 4

    Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.

    de Pablos-Velasco P, Venegas EM, Álvarez Escolá C, et al.

    Pituitary 2020; (23(2)):129-139 doi:10.1007/s11102-019-01012-3.

    PMID: 31823249
  5. 5

    Consensus on criteria for acromegaly diagnosis and remission.

    Giustina A, Biermasz N, Casanueva FF, et al.

    Pituitary 2024; (27(1)):7-22 doi:10.1007/s11102-023-01360-1.

    PMID: 37923946
  6. 6

    Gigantism in a McCune-Albright's syndrome with calcified GH-releasing pituitary adenoma: Case report and literature review.

    Vega-Arroyo M, Tena-Suck ML, Álvarez-Gamiño CTJ, et al.

    International journal of surgery case reports 2018; (53()):61-65 doi:10.1016/j.ijscr.2018.10.030.

    PMID: 30390486
  7. 7

    Pediatric Pituitary Adenomas: Early and Long-Term Surgical Outcome in a Series of 85 Consecutive Patients.

    Barzaghi LR, Losa M, Capitanio JF, et al.

    Neurosurgery 2019; (85(1)):65-74 doi:10.1093/neuros/nyy204.

    PMID: 29790934
  8. 8

    Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.

    Daskareh M, Abbasi F, Emamzadeh N, et al.

    Diagnostics (Basel, Switzerland) 2026; (16(16)) doi:10.3390/diagnostics16162582.

    PMID: 42650985
  9. 9

    Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.

    Taweesomboonyat C, Oearsakul T

    World neurosurgery 2021; (146()):e1360-e1366 doi:10.1016/j.wneu.2020.12.013.

    PMID: 33309643
  10. 10

    Evolving pituitary hormone deficits in primarily isolated GHD: a review and experts' consensus.

    Binder G, Schnabel D, Reinehr T, et al.

    Molecular and cellular pediatrics 2020; (7(1)):16 doi:10.1186/s40348-020-00108-2.

    PMID: 33140249
  11. 11

    Pituitary function at presentation and following therapy in patients with non-functional pituitary macroadenomas: a single centre retrospective cohort study.

    Hussein Z, Marcus HJ, Grieve J, et al.

    Endocrine 2023; (82(1)):143-151 doi:10.1007/s12020-023-03434-3.

    PMID: 37389717
  12. 12

    Outcomes After Gamma Knife Stereotactic Radiosurgery in Pediatric Patients with Cushing Disease or Acromegaly: A Multi-Institutional Study.

    Shrivastava A, Mohammed N, Xu Z, et al.

    World neurosurgery 2019; (125()):e1104-e1113 doi:10.1016/j.wneu.2019.01.252.

    PMID: 30790739
  13. 13

    Progression from isolated growth hormone deficiency to combined pituitary hormone deficiency.

    Cerbone M, Dattani MT

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2017; (37()):19-25 doi:10.1016/j.ghir.2017.10.005.

    PMID: 29107171
  14. 14

    Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly.

    Powlson AS, Gurnell M

    Neuroendocrinology 2016; (103(1)):75-85 doi:10.1159/000438903.

    PMID: 26227953
  15. 15

    Acromegaly, inflammation and cardiovascular disease: a review.

    Wolters TLC, Netea MG, Riksen NP, et al.

    Reviews in endocrine & metabolic disorders 2020; (21(4)):547-568 doi:10.1007/s11154-020-09560-x.

    PMID: 32458292
  16. 16

    Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

    Pivonello R, Auriemma RS, Grasso LF, et al.

    Pituitary 2017; (20(1)):46-62 doi:10.1007/s11102-017-0797-7.

    PMID: 28224405
  17. 17

    Insulin Resistance in Patients With Acromegaly.

    Vila G, Jørgensen JOL, Luger A, Stalla GK

    Frontiers in endocrinology 2019; (10()):509 doi:10.3389/fendo.2019.00509.

    PMID: 31417493
  18. 18

    Airway and sleep disorders in patients with acromegaly.

    Turan O, Akinci B, Ikiz AO, et al.

    The clinical respiratory journal 2018; (12(3)):1003-1010 doi:10.1111/crj.12618.

    PMID: 28224726
  19. 19

    Acromegaly and clinical manifestations.

    Villar-Taibo R, Fernández-Rodríguez E, Bernabéu I

    Vitamins and hormones 2026; (131()):153-193 doi:10.1016/bs.vh.2025.10.004.

    PMID: 41912293
  20. 20

    Bone and Joint Disorders in Acromegaly.

    Claessen KM, Mazziotti G, Biermasz NR, Giustina A

    Neuroendocrinology 2016; (103(1)):86-95 doi:10.1159/000375450.

    PMID: 25633971
  21. 21

    Pituitary Gigantism in an Adolescent Girl With Postsurgical Residual Disease Treated With Lanreotide.

    Kanley AM, Bossert WL, Elrokhsi SH

    JCEM case reports 2025; (3(1)):luae225 doi:10.1210/jcemcr/luae225.

    PMID: 39678651
  22. 22

    Turner Syndrome: transition from childhood to adolescence.

    Kosteria I, Kanaka-Gantenbein C

    Metabolism: clinical and experimental 2018; (86()):145-153 doi:10.1016/j.metabol.2017.12.016.

    PMID: 29309748
  23. 23

    Distinct clinical characteristics and prognosis of pediatric-onset growth hormone-secreting pituitary adenoma (GHPA) patients compared to adult-onset patients.

    Zheng XQ, Yang SM, Xiao TX, et al.

    Endocrine 2025; (87(1)):295-303 doi:10.1007/s12020-024-04044-3.

    PMID: 39317856

This page explains long-term monitoring and transition after treatment for pituitary gigantism for informational purposes only and does not constitute medical advice. Your endocrinologist and care team should tailor hormone tests, imaging, screening, and replacement treatment to your history.

Get notified when new evidence is published on Pituitary gigantism.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.